针对IgG4升高的初级胆道胆道炎的分子气囊疗法:免疫标记物正常化的病例报告
Yun-Ting Lin1, Jeng-Wei Lu2,3,4, Jung-Chun Lin5
1Department of General Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, R.O.C.
In vivo (Athens, Greece)
|April 28, 2025
概括
分子 (H2) 囊显示希望作为一个补充治疗初级胆道胆道炎 (PBC). 这种治疗有助于降低肝酶,改善免疫标记物,并缓解PBC患者对标准护理无反应的症状.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 初级胆道胆炎 (PBC) 是一种慢性自身免疫性肝病.
- Ursodeoxycholic 酸 (UDCA) 是标准的治疗方法,但有些患者反应不佳.
- 分子 (H2) 具有抗氧化和抗炎性质,有利于自身免疫性疾病.
研究的目的:
- 评估H2囊作为PBC辅助疗法的疗效.
- 评估H2对PBC患者肝酶和免疫失调的影响.
- 探索H2在改善PBC患者生活质量的潜力.
主要方法:
- 研究了一例44岁男性患有PBC和肝酶升高的病例报告.
- H2囊治疗是作为UDCA治疗的辅助剂.
- 肝酶,免疫标记物和临床症状被监测了四个月.
主要成果:
- 在H2治疗后观察到AST和ALT水平的显著降低.
- 免疫标记物 (KLRG-1,PD-1,Tim3) 正常化,IgG4水平下降. 免疫标记物 (KLRG-1,PD-1,Tim3) 恢复正常,IgG4水平下降. 免疫标记物 (KLRG-1,PD-1,Tim3) 恢复正常,IgG4水平下降. 免疫标记物 (KLRG-1,PD-1,Tim3) 恢复正常,IgG4水平下降.
- 患者报告疲劳和的改善,在成像上有稳定的纤维化.
结论:
- 2囊可能是PBC的安全有效的辅助治疗.
- 2疗法可以改善肝酶水平,免疫调节和患者的福祉.
- 需要进一步的研究,以建立针对自身免疫性肝脏疾病的H2协议.
相关概念视频
Chronic Pancreatitis II: Collaborative Care
50
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
50
Chronic Bowel Disorders: Introduction
336
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
336
Inflammatory Bowel Disease IV: Pharmacological Management
82
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
82
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
103
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
103


